Effect of diphenylhydantoin on hepatic drug hydroxylation

1974 ◽  
Vol 7 (4) ◽  
pp. 281-285 ◽  
Author(s):  
F. Petruch ◽  
R. V. A. Sch�ppel ◽  
G. Steinhilber
Keyword(s):  
Hepatic Drug ◽  
Drug Hydroxylation

scholarly journals Lack of effect of immunotherapy with BCG and Corynebacterium parvum on hepatic drug hydroxylation in man

1979 ◽  
Vol 39 (4) ◽  
pp. 441-444 ◽  
Author(s):  
H H Wan ◽  
N Thatcher ◽  
P W Mullen ◽  
G N Smith ◽  
P M Wilkinson
Keyword(s):  
Hepatic Drug ◽  
Corynebacterium Parvum ◽  
Drug Hydroxylation

Stimulation of hepatic drug hydroxylation and conjugation by a cutaneously applied PCB-mixture (Clophen A 50)

1977 ◽  
Vol 18 (2) ◽  
pp. 247-251 ◽  
Author(s):  
Jukka Marniemi ◽  
Markku Nokkala ◽  
Harri Vainio ◽  
Kaarlo J.W. Hartiala
Keyword(s):  
Hepatic Drug ◽  
Drug Hydroxylation ◽  
Stimulation Of

scholarly journals Hepatic drug hydroxylation and lipid peroxidation in riboflavin-deficient rats*

1974 ◽  
Vol 140 (3) ◽  
pp. 363-368 ◽  
Author(s):  
J. M. Patel ◽  
N. R. Galdhar ◽  
S. S. Pawar
Keyword(s):  
Lipid Peroxidation ◽  
Adult Female ◽  
Adult Male ◽  
Female Rats ◽  
Hydroxylase Activity ◽  
Riboflavin Deficiency ◽  
Hepatic Drug ◽  
Drug Hydroxylation ◽  
Riboflavin Deficient

The effect of riboflavin deficiency and phenobarbital pretreatment on drug hydroxylation and lipid peroxidation was investigated. A significant decrease in aniline and acetanilide hydroxylation as well as NADPH-linked and ascorbate-induced lipid peroxidation was observed during 4- and 7-week riboflavin deficiency in both adult male and adult female rats. The drug-hydroxylation and lipid-peroxidation activities were further lowered with the increase in riboflavin deficiency. The phenobarbital pretreatment induced aniline and acetanilide hydroxylase activity even in riboflavin-deficient animals. Drug hydroxylation inhibits lipid peroxidation in both deficient and normal rats. The administration of riboflavin was followed by a significant increase in drug hydroxylation and lipid peroxidation.

New Applications of Oleanolic Acid and its Derivatives as Cardioprotective Agents: A Review of their Therapeutic Perspectives

2019 ◽  
Vol 25 (35) ◽  
pp. 3740-3750 ◽  
Author(s):  
Ning Sun ◽  
Dongli Li ◽  
Xiaoqing Chen ◽  
Panpan Wu ◽  
Yu-Jing Lu ◽  
...  
Keyword(s):  
Oleanolic Acid ◽  
Liver Diseases ◽  
Therapeutic Agent ◽  
Heart Diseases ◽  
Pentacyclic Triterpenoids ◽  
Hepatic Drug ◽  
Approved Drugs ◽  
New Applications ◽  
Functional Mechanisms ◽  
Potent Therapeutic Agent

Oleanolic acid is an analogue of pentacyclic triterpenoids. It has been used as a hepatic drug for over 20 years in China. Currently, there are only five approved drugs derived from pentacyclic triterpenoids, including oleanolic acid (liver diseases), asiaticoside (wound healing), glycyrrhizinate (liver diseases), isoglycyrrhizinate (liver disease) and sodium aescinate (hydrocephalus). To understand more about the bioactivity and functional mechanisms of oleanolic acid, it can be developed as a potent therapeutic agent, in particular, for the prevention and treatment of heart diseases that are the leading cause of death for people worldwide. The primary aim of this mini-review is to summarize the new applications of oleanolic acid and its derivatives as cardioprotective agents reported in recent years and to highlight their therapeutic perspectives in cardiovascular diseases.

scholarly journals The effects of the new macrolide antibiotic clarithromycin on hepatic drug- $$$metabolizing enzyme in rats

1992 ◽  
Vol 58 ◽  
pp. 331
Author(s):  
Reiji Kitashiro ◽  
Norimitsu Kurata ◽  
Shinichi Kobayashi ◽  
Yuki Nishimura ◽  
Eiji Uchida ◽  
...  
Keyword(s):  
Macrolide Antibiotic ◽  
Hepatic Drug ◽  
Drug Metabolizing Enzyme ◽  
Metabolizing Enzyme

scholarly journals Preventive Effect of a Polyphenol-Rich Extract from Geranium sanguineum L. on Hepatic Drug Metabolism in Influenza Infected Mice

2020 ◽  
Vol 88 (4) ◽  
pp. 45
Author(s):  
Silviya Abarova ◽  
Lyubka Tancheva ◽  
Rumen Nikolov ◽  
Julia Serkedjieva ◽  
Elitsa Pavlova ◽  
...  
Keyword(s):  
Cytochrome C ◽  
Virus Infection ◽  
Medicinal Plant ◽  
Drug Metabolism ◽  
Thiobarbituric Acid ◽  
Hepatic Drug Metabolism ◽  
Preventive Effect ◽  
Thiobarbituric Acid Reactive Substances ◽  
Hepatic Drug ◽  
Hepatic Monooxygenase

The decreased hepatic drug metabolism (predominately first phase) is one of the essential reasons for numerous side effects and for increased drug toxicity during influenza virus infection (IVI). The present study aims to investigate some mechanisms of the preventive effect of a standardized polyphenol complex from the medicinal plant Geranium sanguineum L. (PPhC) (10 mg/kg nasally). A verified experimental model of IVI A/Aichi/2/68 (H3N2) (4.5 lg LD50) in male ICR (Institute of Cancer Research, USA) mice was used. Changes in hepatic monooxygenase activities as well as nicotinamide adenine dinucleotide phosphate (NADPH)-cytochrome C reductase activity and cytochtome P450 content were studied on days 2, 6, 9, 21 of the infection together with thiobarbituric acid reactive substances in the liver supernatant. Our data clearly demonstrates that IVI affects all components of the electronic chain of cytochrome P-450. N-demethylases and hydroxylases as well as the activity of cytochrome C reductase and cytochtome P-450 content were decreased in the course of the virus infection. This implies that free radicals play an important role not only in the pathogenesis of IVI, but also in the modulation of the hepatic monooxygenase activity. This is also consistent with the established polyphenol complex PPhC from the medicinal plant Geranium sanguineum L. preventive effect against increased thiobarbituric acid reactive substances (TBARS)-levels. PPhC restored most of the monooxygenase activities that were inhibited in IVI animals, even over the control levels, probably via multiple mechanisms that may entail antioxidant activity and selective antiviral and protein-binding effects. In contrast to infected animals, in healthy mice, PPhC showed moderate reversible inhibitory effect on hepatic monooxygenase activities.

EFFECT OF LOW DOSE CYCLOSPORINE AND SIROLIMUS ON HEPATIC DRUG METABOLISM IN THE RAT1

2001 ◽  
Vol 71 (11) ◽  
pp. 1585-1592 ◽  
Author(s):  
Shuang Bai ◽  
Lane J. Brunner ◽  
Stanislaw M. Stepkowski ◽  
Kimberly L. Napoli ◽  
Barry D. Kahan
Keyword(s):  
Drug Metabolism ◽  
Low Dose ◽  
Hepatic Drug Metabolism ◽  
Hepatic Drug

Trimethadione as a Model Drug for the Evaluation of Hepatic Drug-Metabolizing Capacity in Normal and α-Naphthylisothiocyanate-Intoxicated Rats

Pharmacology ◽  
1982 ◽  
Vol 25 (4) ◽  
pp. 202-209 ◽  
Author(s):  
Einosuke Tanaka ◽  
Haruki Kinoshita ◽  
Takemi Yoshida ◽  
Yukio Kuroiwa
Keyword(s):  
Hepatic Drug ◽  
Model Drug
Sign in / Sign up

Export Citation Format

Share Document